[
  {
    "objectID": "quarto/main.html",
    "href": "quarto/main.html",
    "title": "The Financial Toxicity of Universal SGLT2i in HF",
    "section": "",
    "text": "— CONSORT FLOW DIAGRAM DATA (Person-Years) —\nSTEP 1: Total MEPS Population (2021-2023) | N = 69,686\nExclusion 1: No HF Diagnosis | n = 69,141\nSTEP 2: Heart Failure Diagnosis (CCSR: CIR019) | N = 545 (0.8%)\nExclusion 2: Pediatric &lt; 18 | n = 0 (0.0%)\nSTEP 3: Adult Population (Age &gt;= 18) | N = 545 (100.0%)\nExclusion 3: No GDMT Exclusion (Universal Sample Retained) | n = 0\nSTEP 4: Broad HF Cohort | N = 545 (100.0%)\nExclusion 4: Uninsured/Other | n = 12 (2.2%)\nSTEP 5: Final Analytic Cohort (Valid Insurance) | N = 533 (97.8%)\n\n\n\n\n\n\n\nTable 1. Weighted Baseline Demographic and Clinical Characteristics of the U.S. Heart Failure Population (MEPS 2021–2023).\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOverall N = 1,833,138 (100%)1\nCommercial N = 167,779 (9.2%)1\nMedicaid/Dual N = 582,020 (32%)1\nMedicare N = 1,083,339 (59%)1\n\n\n\n\nCurrent SGLT2i Use\n242,314 (13%)\n32,709 (19%)\n72,502 (12%)\n137,103 (13%)\n\n\nAge Category\n\n\n\n\n\n\n\n\n\n\n    &lt;65\n610,131 (33%)\n167,779 (100%)\n367,772 (63%)\n74,580 (6.9%)\n\n\n    65-74\n421,899 (23%)\n0 (0%)\n117,246 (20%)\n304,653 (28%)\n\n\n    75+\n801,109 (44%)\n0 (0%)\n97,003 (17%)\n704,106 (65%)\n\n\nSex\n\n\n\n\n\n\n\n\n\n\n    Male\n840,041 (46%)\n110,333 (66%)\n222,755 (38%)\n506,953 (47%)\n\n\n    Female\n993,097 (54%)\n57,446 (34%)\n359,266 (62%)\n576,386 (53%)\n\n\nRace/Ethnicity\n\n\n\n\n\n\n\n\n\n\n    White\n1,336,511 (73%)\n89,572 (53%)\n353,994 (61%)\n892,945 (82%)\n\n\n    Black\n310,743 (17%)\n57,469 (34%)\n132,585 (23%)\n120,688 (11%)\n\n\n    Hispanic\n90,137 (4.9%)\n0 (0%)\n49,229 (8.5%)\n40,909 (3.8%)\n\n\n    Other\n95,747 (5.2%)\n20,738 (12%)\n46,213 (7.9%)\n28,797 (2.7%)\n\n\nIncome Tier\n\n\n\n\n\n\n\n\n\n\n    Low\n780,289 (43%)\n25,239 (15%)\n396,151 (68%)\n358,899 (33%)\n\n\n    Mid\n541,851 (30%)\n69,908 (42%)\n120,024 (21%)\n351,918 (32%)\n\n\n    High\n510,999 (28%)\n72,632 (43%)\n65,845 (11%)\n372,522 (34%)\n\n\nEmployment Status\n\n\n\n\n\n\n\n\n\n\n    Not Employed\n1,326,914 (79%)\n22,538 (13%)\n493,390 (87%)\n810,986 (86%)\n\n\n    Employed\n351,772 (21%)\n145,241 (87%)\n74,051 (13%)\n132,479 (14%)\n\n\n\n1 n (%)\n\n\nNotes: Data derived from the Medical Expenditure Panel Survey (MEPS), pooled 2021–2023. Values represent weighted national estimates. ‘Income Tier’ is based on poverty line thresholds (&lt;125% Low, 125-400% Mid, &gt;400% High). Employment status reflects status at end-of-year (Round 5).\n\n\n\n\n\n\n\n\n\n\n\n\nTable 2. Breakdown of Annual Out-of-Pocket Healthcare Expenditures by Category and Demographic Subgroup (2023 Inflation-Adjusted Dollars).\n\n\n\n\n\n\n\n\n\n\nTotal Out-of-Pocket Costs\nMedications\nPremiums\nOutpatient/Office\nInpatient\nOther Medical\n\n\n\n\nOverall Population\n\n\nOverall\n$3256 (2552-4153)\n$559 (394-794)\n$888 (602-1308)\n$458 (288-728)\n$205 (108-389)\n$1147 (676-1945)\n\n\nInsurance Type\n\n\nCommercial\n$5971 (3318-10746)\n$373 (239-581)\n$3248 (1679-6284)\n$1129 (510-2501)\n$820 (236-2850)\n$401 (201-798)\n\n\nMedicaid/Dual\n$886 (534-1470)\n$102 (71-146)\n$322 (95-1085)\n$127 (49-329)\n$86 (27-276)\n$250 (113-550)\n\n\nMedicare\n$4108 (3136-5381)\n$834 (570-1220)\n$826 (521-1308)\n$531 (296-955)\n$173 (77-391)\n$1744 (993-3064)\n\n\nAge Group\n\n\n&lt;65\n$2307 (1385-3843)\n$210 (152-289)\n$1112 (560-2209)\n$417 (199-874)\n$307 (119-796)\n$262 (131-521)\n\n\n65-74\n$3431 (2228-5286)\n$765 (471-1242)\n$980 (433-2221)\n$428 (147-1250)\n$106 (52-219)\n$1152 (632-2100)\n\n\n75+\n$3886 (2708-5574)\n$717 (414-1242)\n$668 (426-1048)\n$504 (250-1017)\n$178 (63-506)\n$1818 (900-3671)\n\n\nSex\n\n\nMale\n$3097 (2276-4213)\n$657 (365-1181)\n$948 (629-1430)\n$332 (186-593)\n$144 (100-207)\n$1016 (493-2093)\n\n\nFemale\n$3390 (2304-4987)\n$477 (340-668)\n$836 (441-1587)\n$564 (306-1039)\n$256 (100-654)\n$1257 (593-2664)\n\n\nIncome Level\n\n\nLow\n$1814 (1322-2490)\n$428 (274-670)\n$485 (245-961)\n$303 (143-641)\n$133 (68-262)\n$464 (303-712)\n\n\nMid\n$3684 (2282-5947)\n$607 (337-1092)\n$798 (484-1314)\n$412 (205-829)\n$161 (69-380)\n$1706 (652-4463)\n\n\nHigh\n$5003 (3475-7203)\n$708 (444-1130)\n$1598 (869-2936)\n$742 (365-1508)\n$359 (109-1180)\n$1595 (739-3442)\n\n\nRace/Ethnicity\n\n\nWhite\n$3396 (2556-4510)\n$498 (404-615)\n$787 (524-1183)\n$496 (302-817)\n$205 (108-389)\n$1409 (789-2516)\n\n\nBlack\n$3148 (1480-6694)\n$848 (259-2775)\n$1370 (501-3749)\n$237 (67-840)\n$252 (32-1959)\n$441 (124-1575)\n\n\nHispanic\n$3145 (742-13327)\n$775 (126-4750)\n$782 (125-4878)\n$926 (95-9003)\n$112 (18-702)\n$550 (88-3425)\n\n\nOther\n$1757 (1089-2834)\n$274 (130-574)\n$820 (374-1795)\n$190 (32-1126)\n$138 (28-678)\n$335 (92-1215)\n\n\n\nNotes: Values represent mean annual out-of-pocket (OOP) expenditures. Confidence intervals (95%) were calculated using bootstrap-estimated standard errors (1000 replicates) and log-transformation to account for the right-skewed distribution of healthcare costs. ‘Other Medical’ includes dental, vision, home health, and miscellaneous medical supplies not categorized elsewhere.\n\n\n\n\n\n\n\n\n\n\n\n\nTable 3. Projected Incidence of Financial Toxicity Among Medicare Beneficiaries Under Universal SGLT2i and Post-IRA Policy Scenarios.\n\n\n\n\n\n\n\n\n\n\nBaseline (95% CI)\nBaseline Median Burden\nUniversal SGLT2i (95% CI)\nUniversal Median Burden\nPost-IRA (95% CI)\nPost-IRA Median Burden\nAbsolute Reduction (ARR, %)\nRelative Reduction (RRR, %)\n\n\n\n\nOverall Population\n\n\nAll Medicare Beneficiaries\n30.6 (23.2-39.1)\n5.8%\n35.3 (27.4-44.0)\n8.6%\n33.7 (25.7-42.6)\n7.9%\n1.6\n4.6\n\n\nAge Group\n\n\n&lt;65\n26.6 (--)\n7.4%\n42.4 (--)\n10.1%\n42.4 (--)\n10.1%\n0.0\n0.0\n\n\n65-74\n27.6 (17.4-41.0)\n5.8%\n32.0 (21.6-44.5)\n7.5%\n31.4 (20.9-44.2)\n7.5%\n0.6\n1.7\n\n\n75+\n32.2 (23.2-42.9)\n5.8%\n36.0 (26.3-46.9)\n8.0%\n33.7 (24.2-44.8)\n7.7%\n2.3\n6.3\n\n\nSex\n\n\nMale\n25.9 (17.6-36.3)\n5.7%\n32.8 (22.4-45.2)\n8.4%\n30.0 (19.6-43.1)\n7.7%\n2.8\n8.4\n\n\nFemale\n34.7 (24.3-46.7)\n5.8%\n37.5 (27.2-49.0)\n8.7%\n36.8 (26.6-48.4)\n8.0%\n0.7\n1.7\n\n\nIncome Level\n\n\nLow\n64.9 (45.8-80.1)\n19.6%\n76.7 (55.0-89.9)\n27.5%\n76.2 (54.9-89.4)\n25.1%\n0.5\n0.6\n\n\nMid\n23.4 (12.4-39.6)\n9.0%\n25.9 (15.0-40.9)\n10.7%\n22.4 (12.8-36.2)\n10.6%\n3.5\n13.5\n\n\nHigh\n4.3 (0.4-31.7)\n2.1%\n4.3 (0.4-31.7)\n2.9%\n3.3 (--)\n2.9%\n1.0\n23.6\n\n\nRace/Ethnicity\n\n\nWhite\n26.9 (19.0-36.7)\n5.6%\n32.6 (23.8-42.7)\n7.9%\n31.9 (23.3-42.0)\n7.7%\n0.6\n1.9\n\n\nBlack\n49.7 (30.0-69.5)\n10.6%\n50.5 (30.6-70.2)\n12.5%\n40.3 (17.5-68.4)\n11.8%\n10.2\n20.1\n\n\nHispanic\n43.4 (--)\n5.4%\n43.4 (--)\n5.9%\n43.4 (--)\n5.9%\n0.0\n0.0\n\n\nOther\n44.7 (--)\n12.3%\n44.7 (--)\n15.6%\n44.7 (--)\n15.6%\n0.0\n0.0\n\n\n\nNotes: Financial Toxicity is defined as annual medical expenditures (including premiums) exceeding 20% of post-subsistence income. ‘Universal SGLT2i’ assumes 100% adherence to guideline-directed therapy. ‘Post-IRA’ applies a $2,000 annual pharmacy cap to the Medicare Part D portion. CIs calculated using Logit-transformed intervals based on bootstrap standard errors (1000 replicates). ‘Median Burden’ represents the median percentage of post-subsistence income spent on healthcare. ‘–’ = Suppressed due to statistical unreliability (insufficient sample size or variance instability).\n\n\n\n\n\n\n\n\n\n\n\n\nTable 4. Policy Efficiency Metrics: Economic Number Needed to Harm/Treat (NNH/NNT) and Projected Annual Lives Protected.\n\n\n\n\n\n\n\n\n\n\neNNH (Universal SGLT2i vs Baseline)\neNNT (Post-IRA vs Universal SGLT2i)\nLives Protected (Annual Count)\n\n\n\n\nOverall\n\n\nOverall\n21\n61\n17,692\n\n\nAge Group\n\n\n&lt;65\n6\nNegl.\n0\n\n\n65-74\n23\n180\n1,693\n\n\n75+\n27\n44\n15,999\n\n\nSex\n\n\nMale\n14\n36\n13,943\n\n\nFemale\n36\n154\n3,749\n\n\nIncome Level\n\n\nLow\n8\nNegl.\n1,693\n\n\nMid\n40\n29\n12,250\n\n\nHigh\nNegl.\n99\n3,749\n\n\nRace/Ethnicity\n\n\nWhite\n18\n164\n5,442\n\n\nBlack\n132\n10\n12,250\n\n\nHispanic\nNegl.\nNegl.\n0\n\n\nOther\nNegl.\nNegl.\n0\n\n\n\nNotes: ‘eNNH’ = Economic Number Needed to Harm (number of patients prescribed Universal SGLT2i to cause one new case of toxicity). ‘eNNT’ = Economic Number Needed to Treat (number of patients benefiting from the IRA cap to prevent one case of toxicity). ‘Lives Protected’ = Absolute Risk Reduction × Population Size. ‘Negl.’ = Negligible risk difference (&lt;0.5%).\n\n\n\n\n\n\n\n\n\n\n\n\nFigure 1. Impact of Universal SGLT2i Adherence and IRA Provisions on Financial Toxicity and Cost Composition Among Medicare Beneficiaries.\n\n\n\n\n\n\n\n\n\n\nFigure 2. Reductions in Financial Toxicity by Demographic Subgroup Under the Inflation Reduction Act.\n\n\n\n\n\n\n\n\n\n\nFigure 3. Insurance Coverage Distribution Across Subgroups: Explaining the Differential Impact of IRA Policy.\n\n\n\n\n\n\n\n\n\n\nSupplementary Table 1. Annualized Median Out-of-Pocket Costs for SGLT2i by Insurance Type (2023 Inflation-Adjusted Dollars) with Interquartile Range (IQR).\n\n\n\n\n\n\n\n\n\nInsurance Plan\nAnnual SGLT2i Cost (IQR)\n\n\n\n\nCommercial\n$91 ($91-$91)\n\n\nMedicaid/Dual\n$0 ($0-$0)\n\n\nMedicare\n$532 ($46-$1337)\n\n\n\nNotes: Values are Median (Interquartile Range [Q1-Q3]). Costs are adjusted to 2023 dollars. Calculated using weighted survey quantiles.\n\n\n\n\n\n\n\n\n\n\n\n\nSupplementary Table 2. Projected Annual Out-of-Pocket Savings for Medicare Beneficiaries Stratified by Demographic Subgroups with 95% Bootstrap CIs.\n\n\n\n\n\n\n\n\n\n\nPre-IRA OOP\nPost-IRA OOP\nNet Savings\n% Benefiting\nSavings (Beneficiaries)\n\n\n\n\nOverall Population\n\n\nOverall\n$4615 (3630-5868)\n$4330 (3363-5575)\n$285 (115-706)\n13.1 (7.8-21.0)\n$2179 (1168-4064)\n\n\nAge Group\n\n\n&lt;65\n$1721 (1117-2652)\n$1716 (1113-2645)\n$5 (0-136)\n4.3 (--)\n$119 (--)\n\n\n65-74\n$4950 (3426-7153)\n$4629 (3219-6655)\n$322 (107-970)\n15.4 (8.2-27.1)\n$2090 (816-5353)\n\n\n75+\n$4777 (3432-6648)\n$4478 (3171-6323)\n$299 (88-1018)\n13.0 (6.4-24.5)\n$2297 (966-5460)\n\n\nSex\n\n\nMale\n$4148 (2947-5838)\n$3752 (2660-5292)\n$396 (109-1441)\n13.2 (5.1-30.2)\n$2999 (1260-7139)\n\n\nFemale\n$5026 (3496-7227)\n$4839 (3338-7014)\n$187 (74-475)\n13.0 (8.2-19.9)\n$1445 (665-3139)\n\n\nIncome Level\n\n\nLow\n$3213 (2268-4552)\n$2921 (2162-3946)\n$292 (97-879)\n12.2 (6.5-21.6)\n$2391 (1035-5523)\n\n\nMid\n$5203 (3191-8482)\n$4924 (2928-8282)\n$278 (57-1365)\n13.9 (6.5-27.4)\n$1998 (538-7427)\n\n\nHigh\n$5411 (3757-7793)\n$5127 (3511-7486)\n$284 (84-967)\n13.1 (4.7-31.5)\n$2170 (860-5476)\n\n\nRace/Ethnicity\n\n\nWhite\n$4582 (3450-6084)\n$4456 (3341-5942)\n$126 (56-282)\n11.1 (6.8-17.5)\n$1135 (621-2073)\n\n\nBlack\n$4498 (2381-8496)\n$3173 (1454-6920)\n$1326 (321-5476)\n30.6 (6.0-75.3)\n$4328 (1745-10734)\n\n\nHispanic\n$6999 (1903-25740)\n$6114 (1997-18724)\n$884 (54-14362)\n13.6 (--)\n$6506 (--)\n\n\nOther\n$2762 (1084-7040)\n$2762 (1084-7040)\n$0 (--)\n0.0 (--)\n--\n\n\n\nNotes: Estimates apply specifically to the Medicare beneficiary population. Values are Mean (95% CI). Costs are adjusted to 2023 dollars. CIs calculated using bootstrap standard errors with log-transformation for costs and logit-transformation for proportions. ‘–’ = Suppressed due to statistical unreliability (insufficient sample size or variance instability).\n\n\n\n\n\n\n\n\n\n\n\n\nSupplementary Table 3. Sensitivity Analysis: Projected Financial Toxicity (FT) in the Overall U.S. HF Population (Including Commercial and Medicaid). Note: Impact is diluted as ~40% of the population (Commercial/Medicaid) is ineligible for the IRA cap.\n\n\n\n\n\n\n\n\n\n\nBaseline (95% CI)\nBaseline Median Burden\nUniversal SGLT2i (95% CI)\nUniversal Median Burden\nPost-IRA (95% CI)\nPost-IRA Median Burden\nAbsolute Reduction (ARR, %)\nRelative Reduction (RRR, %)\n\n\n\n\nOverall Population\n\n\nAll Patients\n32.5 (26.0-39.7)\n3.9%\n35.3 (28.4-42.8)\n5.5%\n34.3 (27.5-41.9)\n5.3%\n1.0\n2.7\n\n\nAge Group\n\n\n&lt;65\n32.8 (22.9-44.5)\n2.4%\n34.7 (24.2-46.9)\n2.4%\n34.7 (24.2-46.9)\n2.4%\n0.0\n0.0\n\n\n65-74\n29.3 (18.8-42.7)\n5.4%\n32.4 (21.6-45.5)\n5.7%\n32.0 (21.2-45.2)\n5.7%\n0.4\n1.2\n\n\n75+\n33.9 (25.5-43.5)\n4.6%\n37.2 (28.3-47.0)\n7.7%\n35.2 (26.4-45.2)\n6.7%\n2.0\n5.4\n\n\nSex\n\n\nMale\n26.5 (18.9-35.9)\n3.4%\n30.7 (21.6-41.6)\n4.5%\n29.1 (20.0-40.1)\n4.4%\n1.7\n5.4\n\n\nFemale\n37.5 (29.2-46.6)\n4.2%\n39.1 (30.9-48.1)\n6.1%\n38.8 (30.5-47.7)\n6.1%\n0.4\n1.0\n\n\nIncome Level\n\n\nLow\n61.6 (50.0-72.1)\n11.9%\n67.1 (54.8-77.4)\n20.2%\n66.8 (54.7-77.1)\n20.2%\n0.2\n0.3\n\n\nMid\n15.8 (8.6-27.5)\n5.7%\n17.5 (10.2-28.3)\n6.9%\n15.2 (8.8-25.0)\n6.7%\n2.3\n13.0\n\n\nHigh\n5.6 (1.4-20.2)\n2.0%\n5.6 (1.4-20.2)\n2.3%\n4.9 (1.0-20.9)\n2.3%\n0.7\n13.0\n\n\nRace/Ethnicity\n\n\nWhite\n27.7 (20.5-36.2)\n3.9%\n31.4 (23.7-40.4)\n5.6%\n31.0 (23.3-39.9)\n5.5%\n0.4\n1.3\n\n\nBlack\n47.5 (31.7-63.7)\n5.4%\n47.8 (32.0-64.0)\n5.5%\n43.8 (27.3-61.9)\n4.4%\n3.9\n8.3\n\n\nHispanic\n44.0 (--)\n2.4%\n44.0 (--)\n2.4%\n44.0 (--)\n2.4%\n0.0\n0.0\n\n\nOther\n40.0 (--)\n6.8%\n40.0 (--)\n6.9%\n40.0 (--)\n6.9%\n0.0\n0.0\n\n\nInsurance Type\n\n\nCommercial\n18.1 (5.5-45.6)\n6.8%\n18.1 (5.5-45.6)\n6.9%\n18.1 (5.5-45.6)\n6.9%\n0.0\n0.0\n\n\nMedicaid/Dual\n40.2 (29.1-52.4)\n0.8%\n40.2 (29.1-52.4)\n0.8%\n40.2 (29.1-52.4)\n0.8%\n0.0\n0.0\n\n\nMedicare\n30.6 (23.2-39.1)\n5.8%\n35.3 (27.4-44.0)\n8.6%\n33.7 (25.7-42.6)\n7.9%\n1.6\n4.6\n\n\n\nNotes: CIs calculated using Logit-transformed intervals based on bootstrap standard errors (1000 replicates). ‘Median Burden’ represents the median percentage of post-subsistence income spent on healthcare. ‘–’ = Suppressed due to statistical unreliability (insufficient sample size or variance instability).\n\n\n\n\n\n\n\n\n\n\n\n\nSupplementary Table 4. Projected Incidence of Catastrophic Financial Toxicity (&gt;40% of Income) Among Medicare Beneficiaries.\n\n\n\n\n\n\n\n\n\n\nBaseline (95% CI)\nUniversal SGLT2i (95% CI)\nPost-IRA (95% CI)\nAbsolute Reduction (ARR, %)\nRelative Reduction (RRR, %)\n\n\n\n\nOverall Population\n\n\nAll Medicare Beneficiaries\n22.0 (15.6-30.1)\n22.4 (15.9-30.5)\n20.7 (14.3-29.0)\n1.7\n7.4\n\n\nAge Group\n\n\n&lt;65\n23.9 (--)\n23.9 (--)\n23.9 (--)\n0.0\n0.0\n\n\n65-74\n18.9 (9.6-33.8)\n18.9 (9.6-33.8)\n18.1 (8.9-33.3)\n0.8\n4.1\n\n\n75+\n23.1 (15.6-32.9)\n23.7 (16.0-33.7)\n21.5 (14.1-31.4)\n2.2\n9.3\n\n\nSex\n\n\nMale\n20.3 (12.6-31.0)\n21.1 (13.3-31.7)\n17.8 (10.5-28.8)\n3.3\n15.4\n\n\nFemale\n23.5 (15.0-34.8)\n23.5 (15.0-34.8)\n23.2 (14.7-34.7)\n0.2\n1.0\n\n\nIncome Level\n\n\nLow\n56.3 (39.0-72.3)\n56.3 (39.0-72.3)\n54.8 (37.6-70.9)\n1.6\n2.8\n\n\nMid\n10.2 (2.8-31.0)\n11.4 (3.7-30.0)\n7.9 (0.8-48.3)\n3.5\n30.6\n\n\nHigh\n0.0 (--)\n0.0 (--)\n0.0 (--)\n0.0\n–\n\n\nRace/Ethnicity\n\n\nWhite\n17.2 (11.0-25.8)\n17.6 (11.3-26.4)\n17.5 (11.2-26.2)\n0.2\n0.9\n\n\nBlack\n48.6 (29.0-68.6)\n48.6 (29.0-68.6)\n34.9 (14.5-62.9)\n13.7\n28.1\n\n\nHispanic\n32.7 (--)\n32.7 (--)\n32.7 (--)\n0.0\n0.0\n\n\nOther\n44.7 (--)\n44.7 (--)\n44.7 (--)\n0.0\n0.0\n\n\n\nNotes: Catastrophic toxicity defined as annual person-level medical expenditures (including premiums) exceeding 40% of post-subsistence family income. ‘–’ = Suppressed due to statistical unreliability (insufficient sample size or variance instability).\n\n\n\n\n\n\n\n\n\n\n\n\nSupplementary Figure 1. Reductions in Catastrophic Financial Toxicity (&gt;40%) by Demographic Subgroup."
  }
]